Fluzoparib+Apatinib

Phase 2Small molecule

XXiaohua Wu MD

Fluzoparib+Apatinib is one of 15 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CarcinomaNot yet recruiting

Ovarian CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Ovarian Carcinoma

#DrugCompanyPhaseTrials

Adriamycin

Lenvima

Trexall

Femara

Zejula

GGlaxo Dba Glaxosmithkline

Approved

—6

Cytoxan

BBaxter Healthcare Corporation

Lynparza

2 8

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 2

1 9

Acetylsalicylic Acid

Bayer

Phase 2

1 10

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04517357·100 enrolled

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Unknown status·GGuangxi Medical University·Phase 2·NCT06161272·80 enrolled

Ovarian Carcinoma1 trial

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruiting·XXiaohua Wu MD·Phase 2·NCT05479487·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fluzoparib+Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluzoparib+Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluzoparib+Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiaohua Wu MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXiaohua Wu MD

Fluzoparib+Apatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer2 trials

Ovarian Carcinoma1 trial

References

Drug Info

Quick Facts

Related News